Authors
Latest:
Dr. Tan on the Potential of Elacestrant in the EMERALD Trial in ER+ Breast CancerAntoinette R. Tan, MD, MHSc, discusses the potential of the oral selective estrogen receptor degrader elacestrant being investigated in the phase 3 EMERALD trial in estrogen receptor–positive breast cancer.
Latest:
Treatment Sequencing and Future of GVHDDr Nelson J. Chao reviews treatment sequencing and speculates on the future of the GVHD treatment landscape.
Latest:
Dr Möller on Gender Biases in OncologyMecker G. Möller, MD, discusses the importance of addressing gender biases in oncology.
Latest:
Baptist Health Miami Cancer Institute Celebrates 1000th Patient Treated Using Gamma KnifeBaptist Health Miami Cancer Institute treated its 1000th patient using Gamma Knife radiosurgery, an incisionless radiation therapy that precisely targets a tumor, importantly minimizing damage to otherwise healthy brain tissue.
Latest:
Dr Khan on Optimizing Local Therapy Using MRI and a 12-Gene Expression Assay in DCISSeema A. Khan, MD, discusses 5-year clinical outcomes from the ECOG-ACRIN E4112 trial, which is evaluating the use of MRI and a 12-gene expression assay to optimize local therapy for patients with ductal carcinoma in situ.
Latest:
Dr Fashemi on the Effect of Entinostat on Olaparib Responsiveness in Mouse HRP Ovarian Cancer ModelsBisiayo Fashemi, PhD, discusses how the addition of entinostat to olaparib could help combat PARP inhibitor-resistance in homologous recombination proficient ovarian cancer, as well as the clinical significance of utilizing mouse organoid models to investigate such strategies.
Latest:
Practice Pearls for Treatment of Secondary AML in the Community SettingPanelists discuss how treating secondary AML in the community setting requires a multifaceted approach, emphasizing early diagnosis, risk stratification, timely referral when necessary, and close collaboration with academic centers to provide optimal patient care.
Latest:
Dr Nawfal on the Rationale for Assessing Radiological Tumor Burden in mccRCCRashad Nawfal, MD, discusses radiological tumor burden as an independent prognostic factor for survival in metastatic clear cell renal cell carcinoma.
Latest:
Dr Conlin on Targeting CNS Metastases in the Treatment of Breast CancerAlison K. Conlin, MD, discusses the importance of targeting central nervous system metastases in the treatment of patients with breast cancer, highlighting ongoing treatment investigations for this population.
Latest:
Some Lung Cancer Disparities Lessen in South FloridaRacial/ethnic minorities are often diagnosed with lung cancer at later stages than White patients but that disadvantage is smaller in Hispanic populations.
Latest:
Dr. Nath on the Interim Results of the SIERRA Trial in Relapsed/Refractory AMLRajneesh Nath, MD, discusses the interim results of the phase 3 SIERRA trial in patients with relapsed/refractory acute myeloid leukemia.
Latest:
Future Directions in the Management of Immune ThrombocytopeniaExpert panelists reflect on the advent of newer therapies in immune thrombocytopenia and look toward future evolutions in care.
Latest:
Key Takeaways on Updates in Bladder CancerElizabeth Plimack, MD, MS, FASCO, recaps the discussion with key takeaways on recent updates in bladder cancer.
Latest:
Dr. Bhat on ELEVATE-TN Results in Treatment-Naïve CLLSeema A. Bhat, MD, discusses the results of the phase 3 ELEVATE-TN trial in patients with treatment-naïve CLL.
Latest:
Dr. Bonvalot on the Long-Term Safety of NBTXR3 Plus Radiotherapy in Locally Advanced Soft Tissue SarcomaSylvie Bonvalot, MD, PhD, HDR, discusses the long-term safety of NBTXR3 plus radiotherapy in patients with locally advanced soft tissue sarcoma who were treated in the phase 2/3 Act.In.Sarc trial.
Latest:
Dr. Weinberg on Treating Patients with NTRK Fusions in NSCLCFrank Weinberg, MD, PhD, discusses the treatment options in non–small cell lung cancer harboring NTRK fusions.
Latest:
Exploring Real-World Evidence Presented at ATA 2023Medical professionals discuss the recently published real-world evidence presented at the American Thyroid Association 2023 Conference.
Latest:
From Bench to Bedside: HIF-2α Inhibition in RCCIn 2024, kidney cancer is projected to be one of the top 10 cancers in terms of incidence rate in the United States, with an estimated 81,610 new diagnoses.
Latest:
Dr. Karim on the Rationale for the CheckMate-73L Trial With Ipilimumab/Nivolumab in NSCLCNagla Abdel Karim, MD, discusses the rationale for the phase 3 CheckMate-73L trial that is being conducted in patients with stage III non–small cell lung cancer that is unable or not planned to be removed by surgery.
Latest:
Dr. Andikyan on the Rationale of Using HIPEC in Ovarian CancerVaagn Andikyan, MD, discusses the utilization of hyperthermic intraperitoneal chemotherapy in patients with stage III epithelial ovarian cancer.
Latest:
Early Efficacy Data With RP2 in Advanced Solid TumorsFrancesca Aroldi, discusses the early efficacy data with RP2 in advanced solid tumors.
Latest:
Practice Pearls for Toxicity Management With ADC Therapy in Breast and Gastric CancerShared practical advice on the management of toxicities associated with antibody drug conjugate therapy in both the breast cancer and GI cancer settings.
Latest:
Next Steps With Pembrolizumab/Lenvatinib in Endometrial CancerChristian Marth, MD, PhD, discusses next steps with pembrolizumab and lenvatinib for use in the advanced or recurrent endometrial cancer treatment paradigm.
Latest:
Dr. Gajra on Adverse Effects Associated With CAR T-Cell Therapy in Hematologic MalignanciesAjeet Gajra, MD, FACP, discusses adverse effects associated with CAR T-cell therapy in hematologic malignancies.
Latest:
Rapid Readout: Post Hoc Analysis of Responses to Ponatinib in patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) by Baseline BCR::ABL1 Level and Baseline Mutation Status in the OPTIC TrialDr Smith reviews post-hoc data from the OPTIC trial which assessed the safety and efficacy of ponatinib in patients with CP-CML whose disease was resistant to 2 or more TKIs or who have a T3151 mutation.
Latest:
Managing Toxicities in Short- and Long-Term Treatment with ADCsVijayakrishna Gadi, MD, PhD, discusses short-term and long-term treatments with ADCs.
Latest:
Dr. Sanjeevaiah on the Benefit of Immunotherapy Agents in Gastric CancersAravind R. Sanjeevaiah, MD, discusses the benefit of immunotherapy agents in the treatment of patients with gastric cancers.
Latest:
Mayo Clinic Physicians Seek to Address Bias in Medical EducationThe clinical learning environment for medical trainees is the foundation of medical training programs.
Latest:
ESMO 2021 Updates in Gastric Cancer and Colorectal CancerSam Klempner, MD; Daniel H. Ahn, DO; Nataliya V. Uboha, MD, PhD; and Manish A. Shah, MD, FASCO, review recent updates in second-line gastric cancer, CAR T-cell therapy in solid tumors, and colorectal cancer presented at ESMO 2021.
.jpg?fit=crop&auto=format)
